New llama-derived nanobodies enable selective detection and capture of Z-DNA
Z-DNA is a left-handed DNA conformation that forms transiently at susceptible genomic sequences during processes such as negative supercoiling and active transcription. In the cytoplasm, the innate immune receptor ZBP1 senses Z-form nucleic acids (Z-NAs, which could be DNA or RNA), triggering type I interferon production and programmed cell death. Viral infections, endogenous repetitive-element-derived RNAs, and oxidized mitochondrial DNA can generate Z-NAs, nominating them as ZBP1 agonists. Conversely, ADAR1 is proposed to recognize and edit endogenous Z-RNAs, thereby muting inappropriate innate immune responses. Both proteins engage Z-NAs through Zα domains, which are evolutionarily conserved across vertebrates. Progress in defining Z-NA biology has been limited by near-exclusive reliance on the Z22 monoclonal antibody, the field's principal detection reagent. To expand the availability of distinct, validated anti-Z-NA affinity reagents, we generated and characterized llama-derived nanobodies. Llamas were immunized with brominated poly(dG:dC) DNA, and four recombinant nanobodies (nZ6, nZ6.2, nZ10, and nZ11) that bound the antigen were identified through affinity enrichment and mass spectrometry-guided discovery. The nanobodies selectively recognized Z-DNA in biochemical assays and displayed nanomolar affinities, while homodimerized nZ6.2 achieved picomolar binding. Unlike Zα domains, nZ6.2 does not induce B-to-Z transitions, indicating recognition of pre-existing Z-DNA and immobilized nZ6.2 selectively co-immunoprecipitated ADAR1 and ZBP1 with Z-DNA but not B-DNA. Furthermore, nZ6.2 detected Z-DNA-related structures in a human keratinocyte cell line and in neutrophils from patients with systemic lupus erythematous, producing staining patterns overlapping those of Z22. These renewable, engineerable binders provide orthogonal reagents for investigating Z-NA biology, interferon signaling, and autoimmune disease.
Authors
- John LaCava (ORCID: https://orcid.org/0000-0002-6307-7713)
- Martin S. Taylor (ORCID: https://orcid.org/0000-0001-5824-142X)
- Jonah Da Silva
- Bryant D. Miller (ORCID: https://orcid.org/0009-0006-9145-8499)
- Peter C. Fridy (ORCID: https://orcid.org/0000-0002-8208-9154)
- Hua Jiang (ORCID: https://orcid.org/0009-0008-2059-3057)
- Mathias Ingemann Nielsen (ORCID: https://orcid.org/0000-0002-6823-5354)
- Tomas Mustelin (ORCID: https://orcid.org/0000-0001-5912-8840)
- Joanne Michelle Kahlenberg (ORCID: https://orcid.org/0000-0002-4006-8945)
- Michael P. Rout (ORCID: https://orcid.org/0000-0003-2010-706X)
- Manolis Pasparakis (ORCID: https://orcid.org/0000-0002-9870-0966)
- Brian T. Chait (ORCID: https://orcid.org/0000-0003-3524-557X)
- Laurens Wachsmuth (ORCID: https://orcid.org/0000-0003-1701-9384)
- Mohammad Pourshamsi (ORCID: https://orcid.org/0009-0006-0227-9609)
- Jonathan Kittel
Institutions
- Harvard University (US)
- University of Cologne (DE)
- University of Washington (US)
- Brown University (US)
- University of Michigan (US)
- Michigan Medicine (US)
- Dana-Farber Cancer Institute (US)
- University of Nebraska Medical Center (US)
- Rockefeller University (US)
Publication Details
- Journal
- bioRxiv (Cold Spring Harbor Laboratory)
- Published
- 2026-11-19
- DOI
- https://doi.org/10.64898/2026.11.17.765674
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- preprint